Coronary artery disease (CAD) is prevalent in the CKD population. The methods of diagnosis are the same; however, the treatment parameters and strategies differ. This session focuses on strategies to halt the progression of CAD and a pharmacological plan of care for the patient with CAD and CKD.
Contact hours available until 9/22/2015.
Requirements for Successful Completion: Complete the learning activity in its entirety and complete the online CNE evaluation.
Conflict of Interest Disclosure: Speaker(s) have no disclosures to declare.
Conference Committee Disclosures: Dawn Koonkongsatian – Employee, Fresenius Medical Care Kristin Larson – Employee, NxStage Medical Denise Murcek – Employee, Fresenius Medical Care Beth St. John - Employee, Fresenius Medical Care Lucy Todd – Employee, Baxter Healthcare Kyra Trappett – Employee, DaVita
Commercial Support and Sponsorship: No commercial support or sponsorship declared.
Accreditation Statement: American Nephrology Nurses’ Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.
Summarize the impact of coronary artery disease (CAD) on the person with CKD.
Formulate treatment strategies to control the progression of CAD in the person with CKD.
Generate a pharmacologic treatment plan for the person with CAD and CKD.